InflaRx GmbH   Report issue

For profit Phase 2 Phase 3
Founded: Jena Germany (2007)

Organization Overview

First Clinical Trial
2011
NCT01319903
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

InflaRx GmbH

Active Ingredients

Drugs in Phase 3 Trials (1)

ifx-1 (11 trials)

Drugs in Phase 2 Trials (1)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Granulomatosis with Polyangiitis (Phase 2)

Hidradenitis (Phase 2)

Hidradenitis Suppurativa (Phase 2)

Microscopic Polyangiitis (Phase 2)

Pneumonia (Phase 3)

Pyoderma (Phase 2)

Pyoderma Gangrenosum (Phase 2)

Sepsis (Phase 2)

Shock, Septic (Phase 2)

Systemic Inflammatory Response Syndrome (Phase 2)

Systemic Vasculitis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 2